nach oben

Current Pain and Headache Reports

06.04.2024 | Childhood and Adolescent Headache (S Evers, Section Editor)

Triptans in the Acute Migraine Management of Children and Adolescents: An Update

verfasst von: Jessica Hauser Chatterjee, Heidi K. Blume

Erschienen in: Current Pain and Headache Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To summarize recent findings regarding triptan use in the acute treatment of pediatric migraine.

Recent Findings

Prevalence of pediatric migraine is rising. The American Headache Society and American Academy of Neurology updated guidelines to provide evidence-based recommendations for the treatment of acute migraine in youth. In the setting of a dearth of new randomized controlled trials (RCTs), we review current guidelines, triptan use in the emergency department, and an era of secondary analyses.

Summary

Measuring the efficacy of triptans in pediatric migraine has been challenged by high placebo response rates. Secondary analyses, combining data from multiple RCTs, support that triptans are safe and effective in the treatment of migraine. Triptans are a vital tool and the only FDA-approved migraine-specific treatment available in pediatrics. There is a need for further studies and funding support in pediatric headache medicine.

Nur mit Berechtigung zugänglich

Onofri A, Pensato U, Rosignoli C, et al. Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis. J Headache Pain. 2023;24(1):8. https://doi.org/10.1186/s10194-023-01541-0.CrossRefPubMedPubMedCentral

Nieswand V, Richter M, Gossrau G. Epidemiology of headache in children and adolescents-another type of pandemia. Curr Pain Headache Rep. 2020;24(10):62. https://doi.org/10.1007/s11916-020-00892-6.CrossRefPubMedPubMedCentral

Lateef TM, Merikangas KR, He J, et al. Headache in a national sample of American children: prevalence and comorbidity. J Child Neurol. 2009;24(5):536–43. https://doi.org/10.1177/0883073808327831.CrossRefPubMedPubMedCentral

Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52(12):1088–97. https://doi.org/10.1111/j.1469-8749.2010.03793.x.CrossRefPubMed

Yang Y, Cao Y. Rising trends in the burden of migraine and tension-type headache among adolescents and young adults globally, 1990 to 2019. J Headache Pain. 2023;24(1):94. https://doi.org/10.1186/s10194-023-01634-w.CrossRefPubMedPubMedCentral

Orr SL, Kabbouche MA, O’Brien HL, Kacperski J, Powers SW, Hershey AD. Paediatric migraine: evidence-based management and future directions. Nat Rev Neurol. 2018;14(9):515–27. https://doi.org/10.1038/s41582-018-0042-7.CrossRefPubMed

Leung S, Bulloch B, Young C, et al. Effectiveness of standardized combination therapy for migraine treatment in the pediatric emergency department. Headache. 2013;53(3):171–7. https://doi.org/10.1111/head.12042.CrossRef

Falla K, Kuziek J, Mahnaz SR, Noel M, Ronksley PE, Orr SL. Anxiety and depressive symptoms and disorders in children and adolescents with migraine: a systematic review and meta-analysis. JAMA Pediatr. 2022;176(12):1176–87. https://doi.org/10.1001/jamapediatrics.2022.3940.CrossRefPubMedPubMedCentral

Powers SW, Coffey CS, Chamberlin LA, et al. Prevalence of headache days and disability 3 years after participation in the childhood and adolescent migraine prevention medication trial. JAMA Netw Open. 2021;4(7):1–14. https://doi.org/10.1001/jamanetworkopen.2021.14712.CrossRef

10.

Canfora M, Pallotto IK, Davis JK, et al. More than a headache: lived experience of migraine in youth. Pediatr Neurol. 2023;146:79–84. https://doi.org/10.1016/j.pediatrneurol.2023.05.019.CrossRefPubMed

11.

Abu-Arafeh I. Headache and psychological comorbidities: an appraisal of the evidence. J Clin Med. 2023;12(7). https://doi.org/10.3390/jcm12072683.

12.

Brainstorm Consortium, Anttila V, Bulik-Sullivan B, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360(6395):eaap8757. https://doi.org/10.1126/science.aap8757.CrossRef

13.

Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–76. https://doi.org/10.1016/S1474-4422(18)30322-3.CrossRef

14.

Wöber-Bingöl C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17(6):341. https://doi.org/10.1007/s11916-013-0341-z.CrossRefPubMed

15.

Perry MC, Yaeger SK, Toto RL, Suresh S, Hickey RW. A modern epidemic: increasing pediatric emergency department visits and admissions for headache. Pediatr Neurol. 2018;89:19–25. https://doi.org/10.1016/j.pediatrneurol.2018.07.015.CrossRefPubMedPubMedCentral

16.

Gelfand AA, Goadsby PJ. Treatment of pediatric migraine in the emergency room. Pediatr Neurol. 2012;47(4):233–41. https://doi.org/10.1016/j.pediatrneurol.2012.06.001.CrossRefPubMedPubMedCentral

17.

Raucci U, Della Vecchia N, Ossella C, et al. Management of childhood headache in the emergency department. Review of the literature. Front Neurol. 2019;10:886. https://doi.org/10.3389/fneur.2019.00886. Published 2019 Aug 23.CrossRefPubMedPubMedCentral

18.

Dooley JM, Augustine HF, Brna PM, Digby AM. The prognosis of pediatric headaches - A 30-year follow-up study. Pediatr Neurol. 2014;51(1):85–7. https://doi.org/10.1016/j.pediatrneurol.2014.02.022.CrossRefPubMed

19.

Galinski M, Sidhoum S, Cimerman P, Perrin O, Annequin D, Tourniaire B. Early diagnosis of migraine necessary in children: 10-year follow-up. Pediatr Neurol. 2015;53(4):319–23. https://doi.org/10.1016/j.pediatrneurol.2015.05.013.CrossRefPubMed

20.

Orr SL, Shapiro RE. The elephant in the room: How the underfunding of headache research stunts the field. Headache. 2022;62(9):1234–8. https://doi.org/10.1111/head.14396.CrossRefPubMed

21.

Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine. Drugs. 2000;60(6):1259–87. https://doi.org/10.2165/00003495-200060060-00003.CrossRefPubMed

22.

Humphrey PPA. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008;48(5):685–7. https://doi.org/10.1111/J.1526-4610.2008.01097.X.CrossRefPubMed

23.

Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005;115(1–2):1–4. https://doi.org/10.1016/j.pain.2005.03.008.CrossRefPubMedPubMedCentral

24.

Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56. https://doi.org/10.1002/ana.410330109.CrossRefPubMed

25.

Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25(3):179–83. https://doi.org/10.1111/J.1468-2982.2005.00836.X.CrossRefPubMed

26.

Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023;270(7):3654–66. https://doi.org/10.1007/s00415-023-11706-1.CrossRefPubMedPubMedCentral

27.

Vila-Pueyo M. Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 2018;15(2):291–303. https://doi.org/10.1007/S13311-018-0615-6.CrossRefPubMedPubMedCentral

28.

Goadsby PJ, Akerman S, Storer RJ. Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex. Ann Neurol. 2001;50(6):804–7. https://doi.org/10.1002/ana.10066.CrossRefPubMed

29.

Wiggers A, Ashina H, Hadjikhani N, et al. Brain barriers and their potential role in migraine pathophysiology. J Headache Pain. 2022;23(1):1–10. https://doi.org/10.1186/s10194-021-01365-w.CrossRef

30.

Pleș H, Florian IA, Timis TL, et al. Migraine: advances in the pathogenesis and treatment. Neurol Int. 2023;15(3):1052–105. https://doi.org/10.3390/neurolint15030067.CrossRefPubMedPubMedCentral

31.

Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia. 1989;9(SUPPL. 9):23–33. https://doi.org/10.1111/J.1468-2982.1989.TB00069.X.CrossRefPubMed

32.

Humphrey PPA. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol. 1991;238(1 Supplement). https://doi.org/10.1007/BF01642905.

33.

Humphrey PP, Feniuk W, Perren MJ, et al. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol. 1988;94(4):1123–32. https://doi.org/10.1111/j.1476-5381.1988.tb11630.x.CrossRefPubMedPubMedCentral

34.

Pini LA, Brovia D. Different characteristics of triptans. J Headache Pain. 2004;5(SUPPL. 2). https://doi.org/10.1007/s10194-004-0122-5.

35.

•• Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93:487–99. https://doi.org/10.1212/WNL.0000000000008095. Updated guidelines on acute care, thoughtful systematic review, and endorsed by the American Academy of Pediatrics and Child Neurology Society.

36.

Endorsement SOF. Acute treatment of migraine in children and adolescents. Pediatrics. 2019;144(5):20192762. https://doi.org/10.1542/peds.2019-2762.CrossRef

37.

Practice guideline update: acute treatment of migraine in children and adolescents. https://www.aan.com/Guidelines/home/GuidelineDetail/966. Accessed 30 Jan 2024.

38.

Olesen J. Headache Classification Committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202.CrossRef

39.

Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT 1B/1D agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–25. https://doi.org/10.1111/j.1526-4610.2004.04078.x.CrossRefPubMed

40.

GlaxoSmithKline. Imitrex Tablets (Sumatriptan succinate) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013. www.fda.gov/medwatch.

41.

Maxalt Tablets (Rizatriptan Benzoate). [package insert]. Whitehouse Station, NJ: Merck & Co. Inc; 2007

42.

Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010;9(2):190–204. https://doi.org/10.1016/S1474-4422(09)70303-5.CrossRefPubMed

43.

Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210. https://doi.org/10.1111/J.1468-2982.2007.01288.X.CrossRefPubMed

44.

Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache. 2005;45(3):232–9. https://doi.org/10.1111/j.1526-4610.2005.05050.x.CrossRefPubMed

45.

Ho TW, Fan X, Rodgers A, Lines CR, Winner P, Shapiro RE. Age effects on placebo response rates in clinical trials of acute agents for migraine: Pooled analysis of rizatriptan trials in adults. Cephalalgia. 2009;29(7):711–8. https://doi.org/10.1111/j.1468-2982.2008.01788.x.CrossRefPubMed

46.

• Chanchlani R, Agrawal A, Janjua D, Hafsa SN. The efficacy of different triptans for the treatment of acute headache in pediatric migraine: a systematic review. Indian Pediatr. 2023;60:663–71. Most recent systematic review incorporating most recent studies on triptans in pediatric migraine.CrossRefPubMed

47.

Sun H, Bastings E, Temeck J, et al. Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. JAMA Pediatr. 2013;167(3):243–9. https://doi.org/10.1001/jamapediatrics.2013.872.CrossRefPubMed

48.

Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006;46(1):101–9. https://doi.org/10.1111/J.1526-4610.2006.00313.X.CrossRefPubMed

49.

Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia. 2003;23(7):487–90. https://doi.org/10.1046/j.1468-2982.2003.00528.x.CrossRefPubMed

50.

Winner P, Lewis D, Visser WH, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache. 2002;42(1):49–55. https://doi.org/10.1046/j.1526-4610.2002.02013.x.CrossRefPubMed

51.

Wang G, Tan T, Liu Y, Hong P. Drugs for acute attack of pediatric migraine: a network meta-analysis of randomized controlled trials. Clin Neurol Neurosurg. 2020;195:105853. https://doi.org/10.1016/j.clineuro.2020.105853.CrossRefPubMed

52.

Evers S. The efficacy of triptans in childhood and adolescence migraine. Curr Pain Headache Rep. 2013;17(7):342. https://doi.org/10.1007/s11916-013-0342-y.CrossRefPubMed

53.

Wöber-Bingöl Ç. Pharmacological treatment of acute migraine in adolescents and children. Pediatric Drugs. 2013;15(3):235–46. https://doi.org/10.1007/s40272-013-0019-3.CrossRefPubMed

54.

Richer L, Billinghurst L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016;4(4):CD005220. https://doi.org/10.1002/14651858.CD005220.pub2.CrossRefPubMed

55.

Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed). 2008;336(7650):924–6. https://doi.org/10.1136/bmj.39489.470347.AD.CrossRefPubMed

56.

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:4–10. https://doi.org/10.1136/bmj.i4919.CrossRef

57.

AAN (American Academy of Neurology). Clinical practice guideline process manual. 2011th ed. St. Paul, MN: The American Academy of Neurology; 2011.

58.

Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis. Clin Neurol Neurosurg. 2017;154:74–8. https://doi.org/10.1016/j.clineuro.2017.01.009.CrossRefPubMed

59.

•• Yonker ME, McVige J, Zeitlin L, Visser H. A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension. Headache. 2022;62(9):1207–17. https://doi.org/10.1111/head.14391. First trial in children 6–11 to study zolmitriptan. Notable findings include evidence for headache relief with zolmitriptan in children 6-11, although this was a secondary endpoint and no statistical different found in primary outcome of pain freedom influenced by early termination with slow enrollment during COVID-19 pandemic.

60.

Bachur RG, Monuteaux MC, Neuman MI. A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics. 2015;135(2):232–8. https://doi.org/10.1542/peds.2014-2432.CrossRefPubMed

61.

Richer LP, Laycock K, Millar K, et al. Treatment of children with migraine in emergency departments: national practice variation study. Pediatrics. 2010;126(1):e150–5. https://doi.org/10.1542/PEDS.2009-2337.CrossRefPubMed

62.

Legault G, Eisman H, Shevell MI. Treatment of pediatric status migrainosus: can we prevent the “bounce back.” J Child Neurol. 2011;26(8):949–55. https://doi.org/10.1177/0883073810397631.CrossRefPubMed

63.

Trottier ED, Bailey B, Lucas N, Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. Am J Emerg Med. 2012;30(3):456–63. https://doi.org/10.1016/j.ajem.2010.12.020.CrossRefPubMed

64.

• Genadry KC, Monuteaux MC, Neuman MI, Lowe DA, Lee LK. Disparities and trends in migraine management in pediatric emergency departments, 2009–19. Acad Pediatr. 2022. https://doi.org/10.1016/j.acap.2022.04.007. Most recent investigation of trends of medication use for the treatment of migraine in pediatric emergency departments.

65.

Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med. 1995;25(4):464–9. https://doi.org/10.1016/s0196-0644(95)70259-8.CrossRefPubMed

66.

Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21(3):173–5. https://doi.org/10.1016/S0735-6757(02)42256-5.CrossRefPubMed

67.

• Hauser Chatterjee J, Hartford EA, Law E, Barry D, Blume H. Sumatriptan as a first-line treatment for headache in the pediatric emergency department. Pediatr Neurol. 2023;142:68–75. https://doi.org/10.1016/j.pediatrneurol.2023.01.016. Retrospective study summarizing single-center experience using triptan in the pediatric emergency department. Results suggest there may be a reduced need for IV management, shorter length of stays, and decrease in charges with IN sumatriptan as a first line treatment in the ED.

68.

Yang CP, Liang CS, Chang CM, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(10):1–15. https://doi.org/10.1001/jamanetworkopen.2021.28544.CrossRef

69.

Curran MP, Evans HC, Wagstaff AJ. Intranasal sumatriptan: in adolescents with migraine. CNS Drugs. 2005;19(4):335–6. https://doi.org/10.2165/00023210-200519040-00006.CrossRefPubMed

70.

Lindkvist J, Airaksinen M, Kaukonen AM, Klaukka T, Hoppu K. Evolution of paediatric off-label use after new significant medicines become available for adults: a study on triptans in Finnish children 1994–2007. Br J Clin Pharmacol. 2011;71(6):929–35. https://doi.org/10.1111/j.1365-2125.2010.03881.x.CrossRefPubMedPubMedCentral

71.

Johnson A, Bickel J, Lebel A. Pediatric migraine prescription patterns at a large academic hospital. Pediatr Neurol. 2014;51(5):706–12. https://doi.org/10.1016/j.pediatrneurol.2014.06.018.CrossRefPubMed

72.

Lai LL, Koh L, Ho JAC, Ting A, Obi A. Off-label prescribing for children with migraines in U.S. ambulatory care settings. J Manag Care Spec Pharm. 2017;23(3):382–7. https://doi.org/10.18553/JMCP.2017.23.3.382.CrossRefPubMed

73.

Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106(5):989–97. https://doi.org/10.1542/peds.106.5.989.CrossRefPubMed

74.

Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: A randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46(2):212–22. https://doi.org/10.1111/j.1526-4610.2006.00339.x.CrossRefPubMed

75.

Ahonen K, Hämäläinen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology. 2004;62(6):883–7. https://doi.org/10.1212/01.wnl.0000115105.05966.a7.CrossRefPubMed

76.

Sacco S, Lampl C, Amin FM, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain. 2022;23(1):1–10. https://doi.org/10.1186/s10194-022-01502-z.CrossRef

77.

Vanderpluym JH, Victorio MCC, Oakley CB, Rastogi RG, Orr SL. Beyond the guidelines: a narrative review of treatments on the horizon for migraine in children and adolescents. Neurology. 2023;101(18):788–97. https://doi.org/10.1212/WNL.0000000000207677.CrossRefPubMed

78.

Olesen A, Schytz HW, Ostrowski SR, et al. Low adherence to the guideline for the acute treatment of migraine. Sci Rep. 2022;12(1):8487. https://doi.org/10.1038/s41598-022-12545-2.CrossRefPubMedPubMedCentral

79.

Szperka C. Headache in children and adolescents. CONTINUUM Lifelong Learn Neurol. 2021;27(3):703–31. https://doi.org/10.1212/CON.0000000000000993.CrossRef

80.

US Food and Drug Administration. Pediatric research equity act of 2003. Public Law. 2017;108155. https://congress.gov/108/plaws/publ155/PLAW-108publ155.pdf. Accessed 20 Dec 2023.

Titel: Triptans in the Acute Migraine Management of Children and Adolescents: An Update
verfasst von: Jessica Hauser Chatterjee
Heidi K. Blume
Publikationsdatum: 06.04.2024
Verlag: Springer US
Erschienen in: Current Pain and Headache Reports
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-024-01213-x

Neu im Fachgebiet AINS

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Triptans in the Acute Migraine Management of Children and Adolescents: An Update

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet AINS

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

Update AINS

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet AINS

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

Update AINS